Australian Operations
Include All CSL Sites


75,000 SQ-T oral lyophilisate.
Sublingual tablet of standardised allergen extract of Timothy grass pollen (Phleum pratense).

GRAZAX® is allergy immunotherapy for the disease modifying treatment of grass pollen (Phleum pratense or allergens cross reacting with P. pratense) allergy. This product is only available with a doctor’s prescription.

Who is this information for?
This information is relevant in Australia and is intended for people who have been prescribed this product or health care professionals.

Consumer Medicine Information
The Consumer Medicine Information (CMI) is a leaflet written for consumers. The CMI contains information about the medicine including:
  • What this product is used for
  • How it works
  • How this product is given
  • Side effects
GRAZAX® Consumer Medicine Information (PDF, 0.02MB)

Product Information
Product Information contains information to ensure the safe and effective use of a medicine. This document is approved by the Therapeutic Goods Administration and made available by Seqirus for you if you are a:
  1. qualified healthcare professional; or
  2. consumer, provided you have read the Consumer Medicine Information for the product; want further information on the product; and agree to consult with your healthcare professional if you have any questions in relation to the Product Information.
GRAZAX® Product Information (PDF, 0.07MB)


GRAZAX® is a registered trademark of ALK-Abelló A/S, used under licence.

Last Updated: 20-03-2017
LinkedIn Twitter Facebook Google+
© 2019 Seqirus